We serve Chemical Name:(4-pyrimidin-2-ylphenyl)methanol CAS:100806-78-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4-pyrimidin-2-ylphenyl)methanol
CAS.NO:100806-78-8
Synonyms:4-Pyrimidin-2-ylbenzyl alcohol;Benzenemethanol,4-(2-pyrimidinyl)
Molecular Formula:C11H10N2O
Molecular Weight:186.21000
HS Code:2933599090
Physical and Chemical Properties:
Melting point:76.5ºC
Boiling point:271ºC at 760mmHg
Density:1.201g/cm3
Index of Refraction:1.606
PSA:46.01000
Exact Mass:186.07900
LogP:1.63590
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Pyrimidin-2-ylbenzyl alcohol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzenemethanol,4-(2-pyrimidinyl) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Pyrimidin-2-ylbenzyl alcohol Use and application,Benzenemethanol,4-(2-pyrimidinyl) technical grade,usp/ep/jp grade.
Related News: The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally. (4-pyrimidin-2-ylphenyl)methanol manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. (4-pyrimidin-2-ylphenyl)methanol supplier Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. (4-pyrimidin-2-ylphenyl)methanol vendor The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally. (4-pyrimidin-2-ylphenyl)methanol factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
